Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial

The Lancet

Volumn 384, Issue 9951, 2014, Pages 1349-1357

  Dungan, Kathleen M ^a   Povedano, Santiago Tofé ^b   Forst, Thomas ^c   González, José G González ^d   Atisso, Charles ^e   Sealls, Whitney ^e   Fahrbach, Jessie L ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b Endocrinología   (Spain)

^c Profil Mainz GmbH and Co KG   (Germany)

^d UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^e ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DULAGLUTIDE; GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

AGED; ARTICLE; BACKACHE; BODY MASS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; INTERACTIVE VOICE RESPONSE SYSTEM; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; ANALOGS AND DERIVATIVES; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY;

ANALYSIS OF VARIANCE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FASTING; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; METFORMIN; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84908177336     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)60976-4     Document Type: Article

References (35)

1. RA DeFronzo, RE Ratner, J Han, DD Kim, MS Fineman, AD Baron Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 28 2005 1092 1100
2. DJ Drucker, MA Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
3. DJ Drucker, JB Buse, K Taylor for the DURATION-1 Study Group Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372 2008 1240 1250
4. JJ Meier GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nat Rev Endocrinol 8 2012 728 742
5. A Lund, FK Knop, T Vilsboll Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities Eur J Intern Med 25 2014 407 414
6. T Blevins, J Pullman, J Malloy et al. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes J Clin Endocrinol Metab 96 2011 1301 1310
7. SE Inzucchi, RM Bergenstal, JB Buse et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
8. JB Buse, RM Bergenstal, LC Glass et al. Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial Ann Intern Med 154 2011 103 112
9. Sanofi-Aventis Summary of product characteristics (Lyxumia) http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002445/WC500140401.pdf (accessed March 12, 2014).
10. JH DeVries, SC Bain, HW Rodbard et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1c targets Diabetes Care 35 2012 1446 1454
11. GB Bolli, M Munteanu, S Dotsenko et al. Efficacy and safety of lixisenatide once daily vs placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1) Diabet Med 31 2013 176 184
12. RE Pratley, MA Nauck, AH Barnett for the HARMONY 7 study group Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study Lancet Diabetes Endocrinol 2 2014 289 297
13. C Wysham, T Blevins, R Arakaki et al. Efficacy and safety of dulaglutide added on to pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Diabetes Care 2014 10.2337/dc13-2760 published online May 30.
14. JB Buse, M Nauck, T Forst et al. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet 381 2013 117 124
15. P Barrington, JY Chien, F Tibaldi, HD Showalter, K Schneck, B Ellis LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects Diabetes Obes Metab 13 2011 434 438
16. W Glaesner, AM Vick, R Millican et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein Diabetes Metab Res Rev 26 2010 287 296
17. P Barrington, JY Chien, HD Showalter et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes Diabetes Obes Metab 13 2011 426 433
18. GE Umpierrez, ST Povedano, FP Manghi, L Shurzinske, V Pechtner Efficacy and safety of dulaglutide monotherapy vs metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) Diabetes Care 2014 10.2337/dc13-2759 published online May 19.
19. M Nauck, R Weinstock, GE Umpierrez, B Guerci, Z Skrivanek, Z Milicevic Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5) Diabetes Care 2014 10.2337/dc13-2761 published online April 17.
20. World Medical Association Declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects JAMA 277 1997 925 926
21. Workgroup on Hypoglycemia American Diabetes Association Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia Diabetes Care 28 2005 1245 1249
22. RP Hayes, DR Nelson, ML Meldahl, BH Curtis Ability to perform daily physical activities in individuals with type 2 diabetes and moderate obesity: a preliminary validation of the Impact of Weight on Activities of Daily Living Questionnaire Diabetes Technol Ther 13 2011 705 712
23. RP Hayes, EM Schultz, AN Naegeli, BH Curtis Test-retest, responsiveness, and minimal important change of the ability to perform physical activities of daily living questionnaire in individuals with type 2 diabetes and obesity Diabetes Technol Ther 14 2012 1118 1125
24. R Brooks, R Rabin, F deCharro The measurement and valuation of health status using EQ-5D: a European Perspective. Evidence from the EuroQol BIOMED Research Programme 2003 Kluwer Academic Publishers Dodrecht, Boston, London
25. A Dmitrienko, AC Tamhane, X Wang, X Chen Stepwise gatekeeping procedures in clinical trial applications Biom J 48 2006 984 991
26. A Dmitrienko, AC Tamhane, BL Wiens General multistage gatekeeping procedures Biom J 50 2008 667 677
27. JB Buse, J Rosenstock, G Sesti for the LEAD-6 Study Group Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet 374 2009 39 47
28. B Zinman, J Gerich, JB Buse et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD) Diabetes Care 32 2009 1224 1230
29. A Garber, R Henry, R Ratner for the LEAD-3 (Mono) Study Group Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial Lancet 373 2009 473 481
30. M Nauck, A Frid, K Hermansen et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study Diabetes Care 32 2009 84 90
31. A Garber GLP-1 receptor agonists: why is once weekly inferior to once daily? Lancet Diabetes Endocrinol 2 2014 266 267
32. RE Pratley, M Nauck, T Bailey for the 1860-LIRA-DPP-4 Study Group Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial Lancet 375 2010 1447 1456
33. LL Baggio, Q Huang, TJ Brown, DJ Drucker A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis Diabetes 53 2004 2492 2500
34. W Steinberg, JH DeVries, TA Wadden Jensen CB Svendsen, J Rosenstock Longitudinal monitoring of lipase and amylase in adults with type 2 diabetes and obesity: evidence from two phase 3 randomized clinical trials with the once-daily GLP-1 analog liraglutide [poster presentation at Digestive Disease Week 2012] Gastroenterology 142 suppl 1 2012 S850 S851
35. K Ferdinand, D Calhoun, E Lonn et al. Long-term effects of dulaglutide, a novel GLP-1 agonist, on ambulatory blood pressure and heart rate in patients with type 2 diabetes. Abstract LB-OR-04 J Clin Hypertension 14 2012 488